Sionna Therapeutics Inc. (SION)
11.07
1.07 (10.70%)
At close: Apr 17, 2025, 3:59 PM
11.08
0.05%
After-hours: Apr 17, 2025, 04:04 PM EDT
Company Description
Sionna Therapeutics, Inc. is a biopharmaceutical company.
The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Sionna Therapeutics Inc.
| Country | United States |
| IPO Date | n/a |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Michael Cloonan M.B.A. |
Contact Details
Address: 21 Hickory Drive Suite 500 Waltham, Massachusetts United States | |
| Website | https://www.sionnatx.com/ |
Stock Details
| Ticker Symbol | SION |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | n/a |
| CUSIP Number | n/a |
| ISIN Number | US8294011080 |
| Employer ID | - |
| SIC Code | n/a |
Key Executives
| Name | Position |
|---|---|
| Michael Cloonan M.B.A. | President, Chief Executive Officer & Director |
| Elena H. Ridloff C.F.A. | Chief Financial Officer & Head of Corporate Development |
| Vanya Sagar | Chief People Officer |
| Andy Chu | Vice President of Information & Technology |
| Dr. Charlotte McKee M.D. | Chief Medical Officer |
| Dr. Greg Hurlbut Ph.D. | Co-Founder & Senior Vice President of Discovery Research |
| Dr. Mark Munson Ph.D. | Co-founder & Senior Vice President of Medicinal Chemistry |
| Jennifer Fitzpatrick | Senior Vice President & General Counsel |
| Mara Furlow M.S. | Senior Vice President of Global Regulatory Affairs & Quality |
| Meghan Bagshaw | Vice President of Programs, Portfolio & Operations |